Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Gain insights into what to expect from financial counseling, ensuring you are well-prepared for your sessions and ready to tackle your financial challenges. Be prepared now!
19,590 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
In March 2026, smart japan investors choosing hedged exposure via DXJ are gaining ground as currency moves and reform...
Celebrity-backed meme coins surge on hype and fade on reality. This deep dive explains why the Trump meme coin down t...
Bitwise CIO Matt Hougan outlines a math-driven scenario where Bitcoin could reach $1 million if it commands a 17% sta...
Geopolitical risk surges after reports that Iran’s supreme leader warned of expanding fronts in the Middle East. Mark...
Former Indeed CEO Chris Hyams argues the real AI danger comes from the people steering the technology, not the code. ...
Williams Projects a robust 2026 as U.S. natural gas output and LNG demand surge, underscoring the country’s energy se...
When a CEO sells a sizable block of stock, investors take notice. This article breaks down the numbers behind imax so...
Monday brought a notable move for Circle Internet Group stock as rising demand for USDC underscored the crypto-stable...
A national advocacy group will spend $50 million to back Democratic candidates in pivotal midterm races, arguing that...
Benchmark lowered its Bakkt price target by about 47%, arguing that near-term monetization remains elusive as the com...
A senior executive at AtriCure recently sold 5,000 shares, prompting questions about what this insider move means for...